Dr Rachael Pirie
Dr Harriet Annabella Stanway-Gordon
Dr Hannah Stewart
Dr Kirsty Wilson
Dr Daniel Cole
et al. | An analysis of the physicochemical properties of oral drugs from 2000 to 2022 | 2024 |
|
Matt Anderson
Thomas Carton
Dr Catherine Salvini
Professor Mike Waring
| Micelle-Promoted Reductive Amination of DNA-Conjugated Amines for DNA-Encoded Library Synthesis | 2024 |
|
Dr Hannah Stewart
Dr Mathew Martin
Lan Wang
Dr Eilidh Mackenzie
Professor Mike Waring
et al. | Conformational study into alkyl-aryl ureas to inform drug discovery | 2023 |
|
Dr Harriet Annabella Stanway-Gordon
Jake Odger
Professor Mike Waring
| Development of a Micellar-Promoted Heck Reaction for the Synthesis of DNA-Encoded Libraries | 2023 |
|
Dr Catherine Salvini
Benoit Darlot
Jack Davison
Dr Mathew Martin
Dr Susan Tudhope
et al. | Fragment expansion with NUDELs – poised DNA-encoded libraries | 2023 |
|
Dr Jessica Graham
Dr Harriet Annabella Stanway-Gordon
Professor Mike Waring
| Micelle-Mediated Sonogashira Coupling for DNA-Encoded Library Synthesis | 2023 |
|
Dr Nahoum Anthony
Charlotte Jennings
Dr Mathew Martin
Dr Richard Noble
Nicole Phillips
et al. | Targeting cytotoxic agents through EGFR-mediated covalent binding and release | 2023 |
|
Melanie Uguen
Gemma Davison
James Hunter
Dr Mathew Martin
Dr Shannon Turberville
et al. | Build–Couple–Transform: A paradigm for lead-like library synthesis with scaffold diversity | 2022 |
|
Professor Mike Waring
| Identification and optimization of a novel series of selective PIP5K inhibitors | 2022 |
|
Gemma Davison
Dr Mathew Martin
Dr Shannon Turberville
Selma Dormen
Dr Richard Heath
et al. | Mapping ligand interactions of bromodomains BRD4 and ATAD2 with FragLites and PepLites ─ Halogenated probes of druglike and peptide-like molecular interactions | 2022 |
|
Dr Harriet Stanway-Gordon
Dr Jessica Graham
Professor Mike Waring
| On-DNA Transfer Hydrogenolysis and Hydrogenation for the Synthesis of DNA-Encoded Chemical Libraries | 2022 |
|
Duncan Miller
Tristan Reuillon
Dr Lauren Molyneux
Dr Tim Blackburn
Dr Noel Edwards
et al. | Parallel Optimization of Potency and Pharmacokinetics Leading to the Discovery of a Pyrrole Carboxamide ERK5 Kinase Domain Inhibitor | 2022 |
|
Dr Isaline Castan
Professor Mike Waring
| Scope of on-DNA nucleophilic aromatic substitution on weakly-activated heterocyclic substrates for the synthesis of DNA-encoded libraries | 2022 |
|
Islam Al-Khawaldeh
Dr Christine Basmadjian
Dr Cinzia Bordoni
Dr Suzannah Harnor
Amy Heptinstall
et al. | An alkynylpyrimidine-based covalent inhibitor that targets a unique cysteine in NF-κB-inducing kinase (NIK) | 2021 |
|
Dr Cinzia Bordoni
Daniel Brough
Gemma Davison
James Hunter
Daniel Lopez Fernandez
et al. | Cardiac Ion Channel Inhibition | 2021 |
|
Edwige Picazo
Amy Heptinstall
Dr Celine Cano
Emeritus Professor Bernard Golding
Professor Mike Waring
et al. | Cyclisations and fragmentations in the alkylation of 6-chloro-5-hydroxy-4-aminopyrimidines with aminoalkyl chlorides | 2021 |
|
James Hunter
Dr Harriet Stanway-Gordon
Professor Mike Waring
| Functional group tolerance of a micellar on-DNA Suzuki-Miyaura cross-coupling reaction for DNA-encoded library design | 2021 |
|
James Hunter
Matt Anderson
Dr Isaline Castan
Dr Jessica Graham
Dr Catherine Salvini
et al. | Highly efficient on-DNA amide couplings promoted by micelle forming surfactants for the synthesis of DNA encoded libraries | 2021 |
|
Professor Mike Waring
| Micellar Buchwald-Hartwig coupling of aryl and heteroarylamines for the synthesis of DNA-encoded libraries | 2021 |
|
Melanie Uguen
Professor Mike Waring
| Microwave-assisted synthesis of 4-oxo-2-butenoic acids by aldol-condensation of glyoxylic acid | 2021 |
|
Dr Isaline Castan
Dr Jessica Graham
Dr Catherine Salvini
Dr Harriet Stanway-Gordon
Professor Mike Waring
et al. | On the design of lead-like DNA-encoded chemical libraries | 2021 |
|
James Hunter
Professor Mike Waring
| The maturation of DNA encoded libraries: opportunities for new users | 2021 |
|
Professor Mike Waring
| Alkynyl Benzoxazines and Dihydroquinazolines as Cysteine Targeting Covalent Warheads and Their Application in Identification of Selective Irreversible Kinase Inhibitors | 2020 |
|
Gemma Davison
Dr Mathew Martin
Professor Martin Noble
Professor Mike Waring
| Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease | 2020 |
|
James Hunter
Dr Lisa Prendergast
Professor Mike Waring
| High fidelity Suzuki−Miyaura coupling for the synthesis of DNA encoded libraries enabled by micelle forming surfactants | 2020 |
|
Daniel Wood
Daniel Lopez Fernandez
Leanne Knight
Islam Al-Khawaldeh
Dr Conghao Gai
et al. | FragLites - minimal, halogenated fragments displaying pharmacophore doublets. An efficient approach to druggability assessment and hit generation | 2019 |
|
Professor Mike Waring
| Probe dependency in the determination of ligand binding kinetics at a prototypical G protein-coupled receptor | 2019 |
|
Professor Mike Waring
| Route to Prolonged Residence Time at the Histamine H1 Receptor: Growing from Desloratadine to Rupatadine | 2019 |
|
Professor Mike Waring
| A Genetically Selected Cyclic Peptide Inhibitor of BCL6 Homodimerization | 2018 |
|
Professor Mike Waring
| Cancer II | 2018 |
|
Professor Mike Waring
| Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC to Provide Insight into Small Molecule Targeting of BCL6 | 2018 |
|
Professor Mike Waring
| Practical application of ligand efficiency metrics in lead optimisation | 2018 |
|
Emeritus Professor Bernard Golding
Professor Mike Waring
| The consequences of ‘Brexit’ for drug discovery and development, and the regulatory implications | 2018 |
|
Professor Mike Waring
| Discovery of pyrazolo[1,5-a]pyrimidine B-cell lymphoma 6 (BCL6) binders and optimization to high affinity macrocyclic inhibitors | 2017 |
|
Professor Mike Waring
| Structure-activity relationships of the sustained effects of adenosine A2A receptor agonists driven by slow dissociation kinetics | 2017 |
|
Professor Mike Waring
| Structure-affinity Relationships and Structure-kinetic Relationships of 1,2-Diarylimidazol-4-carboxamide Derivatives as Human Cannabinoid 1 Receptor Antagonists | 2017 |
|
Professor Mike Waring
| Tumour regression and improved gastrointestinal tolerability from controlled release of SN-38 from novel polyoxazoline-modified dendrimers | 2017 |
|
Professor Mike Waring
| AZD5153: a novel bivalent BET bromodomain inhibitor highly active against hematologic malignancies | 2016 |
|
Professor Mike Waring
| Enhanced cytocompatibility and functional group content of poly(L-lysine) dendrimers by grafting with poly(oxazolines) | 2016 |
|
Professor Mike Waring
| Optimisation of a series of bivalent triazolopyridazine based bromodomain and extraterminal inhibitors: the discovery of (3R)-4-[2-[4-[1-(3-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153) | 2016 |
|
Professor Mike Waring
| Potent and selective bivalent inhibitors of BET bromodomains | 2016 |
|
Professor Mike Waring
| Preparation of triazolopyridazine derivatives for use as antiproliferative agents | 2016 |
|
Professor Mike Waring
| A safe and scalable synthesis of 2-hydroxy-3-alkoxypropionates by epoxide ring opening | 2015 |
|
Professor Mike Waring
| An analysis of the attrition of drug candidates from four major pharmaceutical companies | 2015 |
|
Professor Mike Waring
Duncan Miller
| Challenges in the Medicinal Chemical Optimization of Binding Kinetics | 2015 |
|
Professor Mike Waring
| Discovery of a series of 2-(pyridinyl)pyrimidines as potent antagonists of GPR40 | 2015 |
|
Professor Mike Waring
| Discovery of potent, selective small molecule inhibitors of α-subtype of type III phosphatidylinositol-4-kinase (PI4KIIIα) | 2015 |
|
Professor Mike Waring
| An Improved Method for Difluorocyclopropanation of Alkenes | 2014 |
|
Professor Mike Waring
| Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor | 2014 |
|
Professor Mike Waring
Dr James Smith
| Potent, selective small molecule inhibitors of type III phosphatidylinositol-4-kinase α- but not β- inhibit the phosphatidylinositol signaling cascade and cancer cell proliferation. | 2014 |
|
Professor Mike Waring
| The challenges of increasing drug discovery productivity | 2014 |
|
Professor Mike Waring
| A chemistry Wiki to facilitate and enhance chemical design in drug discovery | 2013 |
|
Professor Mike Waring
| Lipophilicity in drug discovery. | 2010 |
|
